Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELEMENT: Elacestrant + Olaparib in gBRCAm HR+/HER2- Metastatic Breast Cancer
NCT06201234Phase 2Recruiting
- Sponsor
- GBG Forschungs
- Start
- Dec 2024
- Primary completion
- Dec 2028
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
A Phase 2 trial of elacestrant in breast cancer, sponsored by GBG Forschungs. Started Dec 2024; status: recruiting.
02
Drugs
elacestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06201234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06201234.